716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy

Thomas Powles, Juergen E. Gschwend, Sergio Bracarda, Daniel Castellano, Marine Gross‐Goupil, J. Bjerggaard Jensen, Ariel Galapo Kann, Hiroyuki Nishiyama, Lydia Makaroff, H. Lassidi, Sanjeev Mariathasan, J. Zhang, Viraj Degaonkar, Joaquim Bellmunt